Deal Structure Guide
Running a Sell-Side M&A Process in Biopharma
Competitive dynamics, buyer psychology, and the timeline that maximizes outcome.
What a sell-side M&A process is
A sell-side M&A process is a structured effort to sell an entire company — not just an asset — to a strategic or financial acquirer. In biopharma, sell-side M&A is typically pursued by companies that have reached a stage where independent commercialization is not viable or not optimal: late-stage biotechs without commercial infrastructure, platform companies whose technology is more valuable inside a larger organization, or commercial-stage companies facing competitive headwinds that a larger parent could mitigate.
The sell-side process is distinct from licensing in a fundamental way: it transfers control. Once the transaction closes, the selling shareholders no longer have any influence over the asset's development, commercialization, or strategic direction. This finality raises the stakes on every dimension of the process — valuation, structure, buyer selection, and timing.
A well-run sell-side process creates competitive tension among multiple potential acquirers, controls information flow and timeline, and positions the company so that buyer psychology drives the outcome upward. A poorly run process — one that starts with a single inbound inquiry, enters exclusive discussions prematurely, or leaks information to the market — consistently destroys value.
Anatomy of a sell-side process
Phase 1: Preparation (6-12 weeks). Before a single buyer is contacted, the company must be prepared for diligence. This means: clean data rooms with organized clinical, regulatory, IP, and financial documentation; a confidential information memorandum (CIM) that tells the company's story in a buyer's language; a management presentation that addresses the strategic rationale, the clinical differentiation, the commercial opportunity, and the integration thesis; and a financial model that the buyer's team can stress-test without losing confidence in the company's rigor.
Phase 2: Buyer Outreach and Indication of Interest (4-6 weeks). The advisor contacts a curated list of potential buyers — typically 15-30 — with a teaser that describes the opportunity without revealing the company's identity. Parties that express interest sign NDAs and receive the CIM. After reviewing the materials, interested buyers submit indications of interest (IOIs) — preliminary, non-binding bids that establish a valuation range.
Phase 3: Due Diligence and Management Presentations (6-10 weeks). Selected buyers (typically 4-8 based on IOI quality) gain access to the data room and meet with management. This is where the competitive dynamic is most critical: buyers must believe that other parties are progressing at a similar pace and with similar enthusiasm.
Phase 4: Final Bids and Definitive Agreement (6-10 weeks). Remaining buyers submit final, binding offers. The seller evaluates bids on multiple dimensions — price, structure, certainty of close, regulatory risk, and employee treatment — and selects a buyer. Definitive agreement negotiation follows, with signing typically occurring within 2-4 weeks of bid selection.
What the data shows about sell-side outcomes
Sell-side M&A outcomes in biopharma are heavily influenced by process design, buyer competition, and timing relative to clinical milestones.
Competitive processes produce premiums. Transactions with three or more final bidders generate median premiums of approximately 30-45% above the initial IOI range. Single-bidder processes show no premium trajectory — the initial price is often the final price.
Pre-data announcements matter. Companies that initiate sell-side processes 3-6 months ahead of a major data readout capture a strategic premium — buyers pay for the optionality of owning the data event. Companies that wait until after the data (whether positive or negative) negotiate from a fundamentally different position.
The CVR tax is real. Approximately 35% of biopharma M&A transactions since 2023 have included a CVR or earnout component. When present, the contingent component represents a median of 20-25% of total deal consideration. As discussed in our CVR guide, the probability-weighted value of this component is significantly less than face value.
Advisor-led processes generate higher outcomes. Companies represented by experienced M&A advisors see median acquisition premiums approximately 20-30% above unadvised transactions. The advisor's value is in process management, buyer psychology, and negotiation leverage — not just introductions.
Benchmark M&A outcomes on Solidus at calculator.ambrosiaventures.co.
What most companies get wrong
The first mistake is engaging with an unsolicited offer without running a process. When a pharma company approaches with an acquisition proposal, the natural impulse is to engage bilaterally. This is almost always value-destructive. The correct response is to use the inbound interest as validation that a sale could generate strong economics — and then run a structured process that includes multiple potential buyers.
The second mistake is timing the process relative to cash runway rather than clinical milestones. Companies that start the sell-side process because they are running out of money negotiate from weakness. Companies that start 12-18 months ahead of their next value inflection point negotiate from strength. The difference in outcome can be 50-100% of deal value.
The third mistake is accepting deal certainty over deal economics. Cash offers with minimal regulatory risk are seductive — especially for boards and investors who have endured years of clinical uncertainty. But accepting a below-market offer for certainty of close is a wealth transfer from the selling shareholders to the buyer. When multiple buyers are engaged, certainty risk is manageable; it should not be traded away at a discount.
The fourth mistake is inadequate CIM construction. The CIM is the company's pitch to potential acquirers. A CIM that reads like a scientific paper — heavy on mechanism, light on market — fails to engage the strategic buyer's evaluation framework. The best CIMs lead with the strategic problem the acquisition solves for the buyer, then support with clinical and commercial evidence.
The fifth mistake is leaking process information. Any indication that the company is "exploring strategic alternatives" — whether through SEC filings, press mentions, or industry rumor — alters buyer behavior. Buyers who know a company is running a formal process adjust their strategy; buyers who know the company is desperate adjust their pricing.
Related Insights
Further reading from our research.
Bring us your transaction.
We’ll meet you at peer level — anywhere in the world.